Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

PURPOSE: To compare the visual and anatomic outcomes of aflibercept versus ranibizumab as a second line treatment for persistent diabetic macular edema (DME) after initial bevacizumab injections. METHODS: In this retrospective cohort study, patients with center-involved DME of ≥ 300 μm thickness aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsaedi, Nasser G, Alselaimy, Ruba M, Alshamrani, Abdulaziz A, AlAjmi, Muhammed, Khandekar, Rajiv, Al-Dhibi, Hassan, Al-Abdullah, Abdulelah A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286127/
https://www.ncbi.nlm.nih.gov/pubmed/34285463
http://dx.doi.org/10.2147/OPTH.S316271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286127/
https://www.ncbi.nlm.nih.gov/pubmed/34285463
http://dx.doi.org/10.2147/OPTH.S316271

Ejemplares similares